From the Editor

Oct 01, 2008
Pharmaceutical Executive
A vision of pharma's next business model is starting to emerge. But how do we get from here to there?
Sep 01, 2008
Pharmaceutical Executive
The United States makes the best medicines in the world. In days to come, that could be a problem.
Aug 01, 2008
Pharmaceutical Executive
FDA preemption is a hot issue for pharma, and it's likely to get hotter. But it's the wrong issue.
Jul 01, 2008
Pharmaceutical Executive
It's not that I disagree with the Obama and McCain healthcare proposals. It's that there's nothing actually there to disagree with
Jun 01, 2008
Pharmaceutical Executive
The great debate on DTC advertising is heating up again. We're going to be hearing a lot about fair balance and risk communication and costs. But what about the patients?
Apr 01, 2008
Pharmaceutical Executive
The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos
Apr 01, 2008
Pharmaceutical Executive
The real question in the Baxter heparin scandal is not who's guilty but whether pharma can get reliable results from a country in chaos
Mar 01, 2008
Pharmaceutical Executive
For pharma to function, it needs a whole network that commands trust. The only alternative is the sort of regulation by mass tort that we've been sliding into in recent years
Feb 01, 2008
Pharmaceutical Executive
New from Pharm Exec: a blog, expanded tech and deals coverage, and a new awards program for emerging pharma leaders
Jan 01, 2008
Pharmaceutical Executive
A new report says FDA is desperately behind on science. At last, a critique we can actually do something about. But will we?
native1_300x100
lorem ipsum